LungLife AI, INC Notice of Results
15 Août 2024 - 8:00AM
RNS Regulatory News
RNS Number : 5072A
LungLife AI, INC
15 August 2024
LungLife AI, Inc.
(the "Company" or
"LungLife")
Notice of Results
Investor
Briefing
LungLife AI (AIM: LLAI), a developer of
clinical diagnostic solutions for the early detection of lung
cancer, will announce its unaudited half-year report for the six
months ended 30 June 2024 on Thursday 22 August 2024.
Investor
presentation
Paul Pagano, Chief Executive Officer, and David
Anderson, Chief Financial Officer, will be hosting a live online
presentation relating to the half-year report via the Investor Meet
Company platform at 5pm (BST) on Thursday 22
August 2024.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am
(BST) the day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet LUNGLIFE AI, INC via:
https://www.investormeetcompany.com/lunglife-ai-inc/register-investor
Investors
who already follow LUNGLIFE AI, INC on the Investor Meet Company
platform will automatically be invited.
A recording of the presentation and
a PDF of the slides used will also be available on the LungLife
website: https://lunglifeai.com/investors/
For further
information please contact:
|
LungLife AI,
Inc.
|
www.lunglifeai.com
|
|
Paul Pagano, CEO
|
investors@lunglifeai.com
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser & Joint
Broker)
|
Tel: +44 (0)20 7597
5970
|
|
Virginia Bull / Lydia Zychowska
/ Sara Wallace
|
|
|
Goodbody (Joint Broker)
Tom Nicholson / Cameron
Duncan
|
Tel: +44 (0) 20 3841
6202
|
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the
Company's LungLB® test is designed to deliver additional
information to clinicians who are evaluating indeterminate lung
nodules. For more information visit
www.lunglifeai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORSFAFALELSEEA
Lunglife Ai (LSE:LLAI)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Lunglife Ai (LSE:LLAI)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
